Cerebain Biotech announced that the company intends to seek FDA approval in conjunction with the development and testing of its medical device for the treatment of Alzheimer's and Dementia. The Company has reached a decisive point in their research and is planning to commence development of the device. As previously expressed, the Company has three options for implantable devices with a bias towards having them as non-invasive as possible.

It is theorized that if a patient's response to the omentum stimulation is successful, the clinical facility should be able to perform various tests for the purpose of setting 'markers' for the patient and then perform the standardized cognitive testing for Alzheimer's patients. The Company has engaged the services of Hamilton Advisors of Great Falls, VA, to support business development goals that will help the company accelerate its research programs, with an emphasis on receiving FDA approval.